Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Sees Large Growth in Short Interest

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 279,178 shares, a growth of 44.1% from the November 30th total of 193,734 shares. Based on an average daily volume of 227,031 shares, the days-to-cover ratio is presently 1.2 days. Approximately 19.9% of the shares of the company are short sold. Approximately 19.9% of the shares of the company are short sold. Based on an average daily volume of 227,031 shares, the days-to-cover ratio is presently 1.2 days.

Institutional Trading of Shuttle Pharmaceuticals

A hedge fund recently bought a new stake in Shuttle Pharmaceuticals stock. Connective Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 100,535 shares of the company’s stock, valued at approximately $357,000. Connective Capital Management LLC owned approximately 9.40% of Shuttle Pharmaceuticals as of its most recent filing with the SEC. 4.58% of the stock is owned by hedge funds and other institutional investors.

Shuttle Pharmaceuticals Trading Up 2.4%

SHPH stock traded up $0.04 on Tuesday, hitting $1.72. 9,050 shares of the company’s stock traded hands, compared to its average volume of 173,397. The stock has a market cap of $2.75 million, a price-to-earnings ratio of -0.15 and a beta of -0.87. Shuttle Pharmaceuticals has a 1-year low of $1.26 and a 1-year high of $25.25. The stock has a fifty day moving average of $2.12 and a 200-day moving average of $3.18.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its quarterly earnings results on Thursday, November 13th. The company reported ($1.05) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on SHPH shares. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Shuttle Pharmaceuticals in a report on Monday, December 15th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Shuttle Pharmaceuticals presently has a consensus rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .